Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249301 · ClinicalTrials.gov registry record · Phase 1
A Study of MLN8054 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT00249301 is a Phase 1 study that was terminated before completion, run by Millennium Pharmaceuticals. The registered enrollment target is 63 participants.
The verdict
NCT00249301, a Phase 1 study, was terminated before completion, sponsored by Millennium Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to determine (1) The side effects or toxicities of MLN8054;(2) The highest dose where side effects or toxicities are not too severe; (3) How MLN8054 is absorbed into the general blood circulation and eliminated from the body; and (4) The levels of MLN8054 in the blood that are needed to inhibit Aurora A kinase.
Interventions
- DRUG MLN8054
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2005-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00249301
The ClinicalTrials.gov registry entry for NCT00249301 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MLN8054 is the first listed.
NCT00249301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00249301 about?
NCT00249301 is a clinical study titled "A Study of MLN8054 in Patients With Advanced Solid Tumors". The purpose of this study is to determine (1) The side effects or toxicities of MLN8054;(2) The highest dose where side effects or toxicities are not too severe; (3) How MLN8054 is absorbed into the general blood circulation and eliminated from the body; and (4) The levels of MLN8054 in the blood th...
What is the current status of trial NCT00249301?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2005-10.
What interventions are being tested in trial NCT00249301?
The interventions under investigation include: MLN8054 (DRUG).
Who is sponsoring clinical trial NCT00249301?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.